New Analyses From Pivotal Phase 3 Studies Show Kyprolis® (Carfilzomib) Allows Patients With Relapsed Multiple Myeloma To Live Longer Without Disease Progression

Cumulative Rates of Complete Response or Better Increased Over Time in Patients Treated With Kyprolis in Combination With Lenalidomide and Dexamethasone (KRd) In a Post-Hoc Analysis, Treatment With KRd for 18 Months Reduced Risk of Progression or Death by 42 Percent During That Period Additional Analyses Showed Kyprolis Plus Dexamethasone (Kd) was Superior to Bortezomib Plus Dexamethasone (Vd) Across Patient Populations

Amgen - Investors - RSS Content